Ascites, AKI, and Albumin
Nov
13
2023
Room 304/306
-
Hynes Convention Center
11:00
AM
- 12:30 PM EST
Speakers
Description
Abstracts
- A RANDOMIZED CONTROLLED TRIAL COMPARING SUSTAINED LOW EFFICIENCY DIALYSIS WITH CONTINUOUS RENAL REPLACEMENT THERAPY FOR SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY IN CRITICALLY ILL PATIENTS WITH CIRRHOSIS (NCT04494542)
- ROLE OF LONG TERM ALBUMIN THERAPY IN TREATMENT OF DECOMPENSATED CIRRHOSIS
- ALBUMIN IS INTERNALIZED BY PRIMARY MONOCYTES USING CLATHRIN-INDEPENDENT ENDOCYTOSIS WHICH IS REQUIRED FOR ITS ANTI-INFLAMMATORY EFFECT.
- HIGH DOSES OF ALBUMIN INCREASES MORTALITY AND COMPLICATIONS IN TERLIPRESSIN TREATED PATIENTS WITH CIRRHOSIS: INSIGHTS FROM THE ATTIRE TRIAL
- SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN RECURRENT ASCITES: A PILOT STUDY
- ALBUMIN DOSING WITH TERLIPRESSIN FOR THE TREATMENT OF HRS-AKI: A DOUBLE-EDGED SWORD.